Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate

The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma

(2020) Geert J.L.H. van Leenders et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance

(2019) Masashi Kato et al.   PROSTATE

Cases Having a Gleason Score 3+4=7 With

(2019) Shun Sato et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Active surveillance in intermediate risk prostate cancer

(2019) Laurence Klotz   BJU INTERNATIONAL

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

(2018) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories

(2017) Laura H. Porter et al.   EUROPEAN UROLOGY

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

(2017) Philip Cornford et al.   EUROPEAN UROLOGY

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

(2017) Nicolas Mottet et al.   EUROPEAN UROLOGY

Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance

(2017) Nathan Perlis et al.   JOURNAL OF UROLOGY

Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer

(2017) Charlotte F Kweldam et al.   MODERN PATHOLOGY

Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma

(2016) Charlotte F. Kweldam et al.   EUROPEAN JOURNAL OF CANCER

Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement

(2016) Ronald C. Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Prostate Cancer, Version 1.2016

(2016) James L. Mohler et al.   Journal of the National Comprehensive Cancer Network

The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation

(2016) Masashi Kato et al.   MODERN PATHOLOGY

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

(2016) Freddie C. Hamdy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer

(2015) Laurence Klotz et al.   JOURNAL OF CLINICAL ONCOLOGY

Gleason Score 3 + 4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen

(2014) Cheng Cheng Huang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial

(2014) J Athene Lane et al.   LANCET ONCOLOGY

Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens

(2014) Kyosuke Kimura et al.   PROSTATE

Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?

(2014) Tao Zhao et al.   PROSTATE

Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer?

(2012) H. Ballentine Carter et al.   JOURNAL OF CLINICAL ONCOLOGY